ascopubs.org

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.

BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
The American Journal of Managed Care

Low-Dose Aspirin Cuts Recurrence Risk in PI3K-Altered Colorectal Cancer

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
EurekAlert!

PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
ascopubs.org

Artificial intelligence–enhanced biomarker analysis of WNT, TGF-β, and PI3K pathway alterations in FOLFOX-treated early-onset colorectal cancer in high-risk populations.

WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
News Medical

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Medscape

Did Hyperglycemia Affect Inavolisib-Efficacy in Patients With Breast Cancer?

Exploratory data show inavolisib benefits persist regardless of hyperglycemia in PIK3CA-mutated breast cancer, with ...